Covered recipient · General Payments record
DAVID M PARISER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$57,848.64
64 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $54,473.50 | 21 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,220.00 | 2 |
| Food and Beverage | $1,170.48 | 38 |
| Travel and Lodging | $984.66 | 3 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| LEO Pharma Inc. | $15,059.21 | 5 |
| Regeneron Healthcare Solutions, Inc. | $11,780.00 | 8 |
| Janssen Biotech, Inc. | $7,679.09 | 12 |
| GENZYME CORPORATION | $5,491.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,960.00 | 2 |
| Biofrontera Inc. | $3,037.50 | 1 |
| Janssen Scientific Affairs, LLC | $3,000.00 | 4 |
| Mindera Corp | $2,475.00 | 1 |
| UCB, Inc. | $2,159.82 | 2 |
| Novartis Pharmaceuticals Corporation | $823.42 | 3 |
| Almirall LLC | $800.00 | 1 |
| AbbVie Inc. | $193.12 | 11 |
| E.R. Squibb & Sons, L.L.C. | $124.30 | 2 |
| Lilly USA, LLC | $76.17 | 4 |
| Incyte Corporation | $75.26 | 2 |
| Journey Medical Corporation | $42.01 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $31.95 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.11 | 1 |
| Amgen Inc. | $19.68 | 1 |
Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID M PARISER
NPI 1417050717 · CMS profile ID 109604
Allopathic & Osteopathic Physicians / Dermatology
NORFOLK, VA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID M PARISER, NPI 1417050717, CMS profile ID 109604. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAVID M PARISER, NPI 1417050717, CMS profile ID 109604. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAVID M PARISER, NPI 1417050717, CMS profile ID 109604, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417050717?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
64 matching records · $57,848.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–64 of 64.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Biofrontera Inc. | $3,037.50 | 06/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853693389 | CMS |
| AbbVie Inc. | $17.33 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795506907 | CMS |
| Lilly USA, LLC | $16.39 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819044971 | CMS |
| Janssen Biotech, Inc. | $1.74 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788209441 | CMS |
| Janssen Biotech, Inc. | $39.04 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788209443 | CMS |
| AbbVie Inc. | $24.69 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795506901 | CMS |
| Almirall LLC | $800.00 | 05/25/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819699589 | CMS |
| Janssen Biotech, Inc. | $11.89 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788209439 | CMS |
| AbbVie Inc. | $16.03 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795506895 | CMS |
| LEO Pharma Inc. | $12.06 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842239565 | CMS |
| LEO Pharma Inc. | $7,500.00 | 04/29/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842239555 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,100.00 | 03/12/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809611281 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,100.00 | 02/12/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809611279 | CMS |
| Janssen Biotech, Inc. | $1,350.00 | 02/02/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788209423 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $603,533.76 | 243 |
| PY2024 | Recipient | $1,093.05 | 10 |
| PY2024 | Principal investigator | $717,395.76 | 316 |
| PY2023 | Recipient | $3,383.18 | 16 |
| PY2023 | Principal investigator | $565,018.89 | 264 |
| PY2022 | Recipient | $6,152.32 | 8 |
| PY2022 | Principal investigator | $393,501.55 | 160 |
| PY2021 | Recipient | $10,250.67 | 14 |
| PY2021 | Principal investigator | $1,504,763.82 | 222 |
| PY2020 | Recipient | $29,446.02 | 12 |
| PY2020 | Principal investigator | $1,483,056.25 | 261 |
| PY2019 | Recipient | $56,019.66 | 30 |
| PY2019 | Principal investigator | $1,432,919.10 | 255 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
243 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615120 |
| Principal investigator 1 | Incyte Corporation | $1,487.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615124 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615128 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615169 |
| Principal investigator 1 | Incyte Corporation | $1,268.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615188 |
| Principal investigator 1 | Incyte Corporation | $1,268.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615192 |
| Principal investigator 1 | Incyte Corporation | $1,268.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615196 |
| Principal investigator 1 | Incyte Corporation | $1,268.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615199 |
| Principal investigator 1 | Incyte Corporation | $1,626.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615203 |
| Principal investigator 1 | Incyte Corporation | $1,626.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615208 |
| Principal investigator 1 | Incyte Corporation | $1,626.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615214 |
| Principal investigator 1 | Incyte Corporation | $2,179.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615222 |
| Principal investigator 1 | Incyte Corporation | $2,179.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615225 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615259 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615265 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615269 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615272 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615276 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 12/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615280 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $275.00 | 12/17/2025 | Covered Recipient Teaching Hospital Cleveland Clinic Hospital | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220815222 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,325.55 | 12/17/2025 | Covered Recipient Teaching Hospital Cleveland Clinic Hospital | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220815224 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,600.00 | 12/15/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795127 |
| Principal investigator 1 | Incyte Corporation | $2,166.45 | 12/08/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615173 |
| Principal investigator 1 | Incyte Corporation | $6,099.80 | 12/05/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615177 |
| Principal investigator 1 | ABBVIE INC. | $4,190.80 | 12/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202528770 |
| Principal investigator 1 | ABBVIE INC. | $3,073.80 | 12/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202528772 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,157.19 | 12/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184268995 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 12/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289174 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $375.00 | 12/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289176 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615165 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615184 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615284 |
| Principal investigator 1 | Incyte Corporation | $21.33 | 12/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615301 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,770.30 | 12/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289039 |
| Principal investigator 1 | Incyte Corporation | $128.20 | 11/26/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240615063 |
| Principal investigator 1 | Incyte Corporation | $1,423.10 | 11/24/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615181 |
| Principal investigator 1 | Incyte Corporation | $2,394.00 | 11/24/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615256 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615072 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615143 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615147 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615153 |
| Principal investigator 1 | Incyte Corporation | $1,666.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615249 |
| Principal investigator 1 | Incyte Corporation | $1,666.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615252 |
| Principal investigator 1 | Incyte Corporation | $337.20 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615287 |
| Principal investigator 1 | Incyte Corporation | $1,366.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615293 |
| Principal investigator 1 | Incyte Corporation | $1,626.00 | 11/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615297 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 11/20/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240615059 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 11/20/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240615067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,021.02 | 11/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184258257 |
| Principal investigator 1 | ABBVIE INC. | $22,097.60 | 11/05/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521853 |
| Principal investigator 1 | ABBVIE INC. | $11,314.70 | 11/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202520369 |
| Principal investigator 1 | Biofrontera Inc. | $530.00 | 10/31/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). | No dispute reported | 06/30/2026 | 1208907720 |
| Principal investigator 1 | Incyte Corporation | $1,153.80 | 10/28/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240615055 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,364.80 | 10/23/2025 | Non-covered Recipient Entity Virginia Clinic Rsrch Inc. | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175294055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,040.91 | 10/23/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252524 |
| Principal investigator 1 | Incyte Corporation | $68.30 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615077 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615081 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615085 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615090 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615094 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615098 |
| Principal investigator 1 | Incyte Corporation | $81.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615102 |
| Principal investigator 1 | Incyte Corporation | $81.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615107 |
| Principal investigator 1 | Incyte Corporation | $1,626.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615110 |
| Principal investigator 1 | Incyte Corporation | $1,626.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615113 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615132 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615136 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615139 |
| Principal investigator 1 | Incyte Corporation | $98.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615156 |
| Principal investigator 1 | Incyte Corporation | $98.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615161 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615230 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615234 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615238 |
| Principal investigator 1 | Incyte Corporation | $1,666.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615241 |
| Principal investigator 1 | Incyte Corporation | $1,666.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615245 |
| Principal investigator 1 | Incyte Corporation | $216.00 | 10/22/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615304 |
| Principal investigator 1 | Incyte Corporation | $1,331.90 | 10/20/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615116 |
| Principal investigator 1 | Incyte Corporation | $2,394.00 | 10/20/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615218 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 10/20/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184251544 |
| Principal investigator 1 | ABBVIE INC. | $16,416.10 | 10/09/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202514803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $680.85 | 10/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184244589 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,836.60 | 10/01/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795125 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,635.80 | 10/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286065 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614945 |
| Principal investigator 1 | Incyte Corporation | $98.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614950 |
| Principal investigator 1 | Incyte Corporation | $98.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614954 |
| Principal investigator 1 | Incyte Corporation | $1,416.70 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614957 |
| Principal investigator 1 | Incyte Corporation | $1,666.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614960 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614964 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614968 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614972 |
| Principal investigator 1 | Incyte Corporation | $1,585.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614976 |
| Principal investigator 1 | Incyte Corporation | $98.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614981 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614985 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615022 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615025 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615030 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615033 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615037 |
| Principal investigator 1 | Incyte Corporation | $2,445.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615040 |
| Principal investigator 1 | Incyte Corporation | $98.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615045 |
| Principal investigator 1 | Incyte Corporation | $1,742.00 | 09/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240615048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184241122 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 09/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614990 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 09/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240614995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $813.96 | 08/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184229915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $859.35 | 08/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184226519 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,687.80 | 08/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283689 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,403.10 | 08/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,072.00 | 07/31/2025 | Non-covered Recipient Entity Virginia Clinic Rsrch Inc. | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175294114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $272.34 | 07/31/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184222750 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 07/28/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614999 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 07/28/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615008 |
| Principal investigator 1 | Incyte Corporation | $1,928.75 | 07/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615005 |
| Principal investigator 1 | Incyte Corporation | $1,624.00 | 07/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615011 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 07/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615014 |
| Principal investigator 1 | Incyte Corporation | $2,231.00 | 07/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615018 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 07/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240615052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 07/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,157.19 | 07/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184212789 |
| Principal investigator 1 | ABBVIE INC. | $6,788.80 | 07/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496261 |
| Principal investigator 1 | ABBVIE INC. | $4,832.03 | 07/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202496369 |
| Principal investigator 1 | Incyte Corporation | $1,451.60 | 06/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/18/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184208989 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $136.17 | 06/12/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184206167 |
| Principal investigator 1 | Eli Lilly and Company | $5,955.40 | 06/05/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187892234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $703.29 | 06/05/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184204109 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,694.55 | 06/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280722 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,290.90 | 06/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280742 |
| Principal investigator 1 | ABBVIE INC. | $3,305.20 | 06/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202487613 |
| Principal investigator 1 | Incyte Corporation | $39.14 | 06/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,213.29 | 05/28/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184198813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 05/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 05/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 05/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 05/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 05/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658260 |
| Principal investigator 1 | Incyte Corporation | $2,119.45 | 05/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614857 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $272.34 | 05/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184194577 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 05/14/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228784204 |
| Principal investigator 1 | ABBVIE INC. | $9,084.60 | 05/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483321 |
| Principal investigator 1 | ABBVIE INC. | $7,716.03 | 05/06/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481801 |
| Principal investigator 1 | Incyte Corporation | $1,340.05 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614861 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614865 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614869 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614871 |
| Principal investigator 1 | Incyte Corporation | $160.30 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614880 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614883 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614886 |
| Principal investigator 1 | Incyte Corporation | $8.48 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614905 |
| Principal investigator 1 | Incyte Corporation | $2,231.00 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614929 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614932 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614935 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,133.10 | 05/01/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,779.20 | 04/22/2025 | Non-covered Recipient Entity Virginia Clinic Rsrch Inc. | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175294176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,131.69 | 04/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184183212 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,978.00 | 04/11/2025 | Non-covered Recipient Entity Virginia Clinical Research, Inc | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235991945 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,872.40 | 04/11/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277998 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,905.60 | 04/04/2025 | Non-covered Recipient Entity Virginia Clinical Research, Inc | A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) | No dispute reported | 06/30/2026 | 1235991947 |
| Principal investigator 1 | ABBVIE INC. | $10,637.80 | 04/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470576 |
| Principal investigator 1 | ABBVIE INC. | $2,350.70 | 04/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202470781 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614889 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614897 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614900 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614908 |
| Principal investigator 1 | Incyte Corporation | $116.60 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614911 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614915 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614919 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614923 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614927 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614938 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 04/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614942 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.73 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.44 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.94 | 03/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 03/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174282 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 03/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174284 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $317.73 | 03/19/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174466 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,873.60 | 03/13/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795121 |
| Principal investigator 1 | Eli Lilly and Company | $93,358.00 | 03/11/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187892918 |
| Principal investigator 1 | ABBVIE INC. | $2,518.40 | 03/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202459791 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,441.40 | 03/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276119 |
| Principal investigator 1 | ABBVIE INC. | $8,586.70 | 03/06/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202456876 |
| Principal investigator 1 | ABBVIE INC. | $5,805.00 | 03/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202455643 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $768.57 | 03/04/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184156668 |
| Principal investigator 1 | Incyte Corporation | $1,293.65 | 03/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614770 |
| Principal investigator 1 | Incyte Corporation | $1,631.00 | 03/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614790 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 03/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614817 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 03/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614820 |
| Principal investigator 1 | Incyte Corporation | $109.52 | 03/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614831 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 03/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,975.70 | 02/26/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 02/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 02/25/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658236 |
| Principal investigator 1 | Eli Lilly and Company | $2,577.47 | 02/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187892236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $272.34 | 02/25/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $904.74 | 02/11/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184153162 |
| Principal investigator 1 | ABBVIE INC. | $2,671.40 | 02/06/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447024 |
| Principal investigator 1 | ABBVIE INC. | $4,198.30 | 02/05/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202444047 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $175.00 | 02/01/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795117 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,810.81 | 02/01/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH, INC | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190306065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658220 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.73 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.88 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.88 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.88 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.88 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.94 | 01/27/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220658232 |
| Principal investigator 1 | Incyte Corporation | $1,451.60 | 01/27/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614827 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,092.70 | 01/24/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274455 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,181.90 | 01/23/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795119 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,448.67 | 01/22/2025 | Non-covered Recipient Entity Virginia Clinic Rsrch Inc. | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175294158 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,349.46 | 01/21/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $181.56 | 01/17/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148051 |
| Principal investigator 1 | Incyte Corporation | $1,631.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614766 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614774 |
| Principal investigator 1 | Incyte Corporation | $1,528.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614779 |
| Principal investigator 1 | Incyte Corporation | $1,133.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614784 |
| Principal investigator 1 | Incyte Corporation | $1,631.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614787 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614823 |
| Principal investigator 1 | Incyte Corporation | $1,631.00 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614853 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $39.76 | 01/15/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH, INC | A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1190306063 |
| Principal investigator 1 | PFIZER INC. | $1,097.10 | 01/15/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228800069 |
| Principal investigator 1 | Eli Lilly and Company | $94.30 | 01/09/2025 | Non-covered Recipient Entity NEW HORIZON RESEARCH CENTER | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187885916 |
| Principal investigator 1 | Eli Lilly and Company | $30,060.20 | 01/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187892238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $363.12 | 01/07/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184145712 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,226.90 | 01/03/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273509 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614794 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614799 |
| Principal investigator 1 | Incyte Corporation | $2.12 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614803 |
| Principal investigator 1 | Incyte Corporation | $10.30 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614807 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614811 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614815 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614839 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614843 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity VIRGINIA CLINICAL RESEARCH INC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240614847 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $175.00 | 01/01/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | EvasayilTM : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome | No dispute reported | 06/30/2026 | 1220795115 |
| Principal investigator 1 | PFIZER INC. | $1,081.00 | 01/01/2025 | Non-covered Recipient Entity Virginia Clinical Research Inc | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228799971 |